An investigation by the Office of the Inspector General found the practice purchased Botox that wasn’t approved by the Food and Drug Administration through interstate commerce from 2010 to 2013.
Under federal law, no form of Botox may be commercially distributed for human use unless approved by the FDA. The only company approved and licensed by the FDA to commercially manufacture the drug is Parsipanny-Troy Hills, N.J.-based Allergen, according to the article.
The practice was given three years of federal probation. No fine was imposed, given the verdict and subsequent fine in the parallel civil case brought by the U.S. Attorney’s Office, according to the article.
More articles on legal and regulatory issues:
Bloomberg: Lawyers predict more cases arising from Medicaid overpayment rule
Alere sues Abbott Laboratories over $5.8B pending acquisition
Judge denies request to stay Cabell Huntington, St. Mary’s Medical Center merger
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
